Novo Nordisk's experimental obesity drug CagriSema demonstrated an average 25% weight loss among adult women after 68 weeks in a new analysis following a late-stage trial. The drug, combining semaglutide and cagrilintide, also showed significant weight loss across different menopause stages, with reductions in abdominal fat. This next-generation treatment is expected to launch early next year and aims to improve on the benefits of Novo's existing GLP-1 drug Wegovy. Despite mixed investor reactions to earlier trial results, analysts forecast CagriSema could generate nearly $12 billion in obesity drug sales by 2028.
Novo Nordisk's stock price on Pluang is USD 38.81 as of Oct 20, 2026 20:01 WIB, showing a 1.02% increase for the day. The company's market cap stands at $169.97 billion, reflecting its significant presence in the health sector. Despite mixed investor sentiment with 67% selling activity on Pluang, Novo Nordisk remains a major player in obesity drug development.
Eli Lilly reported strong Q2 earnings with revenue up 47.67% and EPS beating estimates, driven by high sales of its obesity drug Mounjaro. The company raised its 2026 revenue guidance to $85-$87 billion and is optimistic about the upcoming U.S. filin...
The obesity treatment landscape is rapidly evolving with over 200 companies developing more than 200 pipeline drugs, including late-stage and early-stage clinical trials. Major pharmaceutical firms like Novo Nordisk and Eli Lilly are leading with inn...
